Recon: Lilly plans $6.5B Texas API site; Moderna says updated COVID jab induces strong immune response

Recon

ReconJason Scott

Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States